JP2014527072A - ウイルスタンパク質の集合を制御するための方法および組成物 - Google Patents

ウイルスタンパク質の集合を制御するための方法および組成物 Download PDF

Info

Publication number
JP2014527072A
JP2014527072A JP2014529962A JP2014529962A JP2014527072A JP 2014527072 A JP2014527072 A JP 2014527072A JP 2014529962 A JP2014529962 A JP 2014529962A JP 2014529962 A JP2014529962 A JP 2014529962A JP 2014527072 A JP2014527072 A JP 2014527072A
Authority
JP
Japan
Prior art keywords
core protein
seq
modified
protein
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014529962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527072A5 (enExample
Inventor
ロス リオス， ミグエル デ
ロス リオス， ステファニー デ
ジャセク オストロウスキ，
ケネス ジェイ． オー，
イラン ジップキン，
Original Assignee
バイオメド リアルティー， エル．ピー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオメド リアルティー， エル．ピー． filed Critical バイオメド リアルティー， エル．ピー．
Publication of JP2014527072A publication Critical patent/JP2014527072A/ja
Publication of JP2014527072A5 publication Critical patent/JP2014527072A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2014529962A 2011-09-09 2012-09-10 ウイルスタンパク質の集合を制御するための方法および組成物 Pending JP2014527072A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532986P 2011-09-09 2011-09-09
US61/532,986 2011-09-09
PCT/US2012/054534 WO2013036973A2 (en) 2011-09-09 2012-09-10 Methods and compositions for controlling assembly of viral proteins

Publications (2)

Publication Number Publication Date
JP2014527072A true JP2014527072A (ja) 2014-10-09
JP2014527072A5 JP2014527072A5 (enExample) 2015-11-05

Family

ID=47832822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014529962A Pending JP2014527072A (ja) 2011-09-09 2012-09-10 ウイルスタンパク質の集合を制御するための方法および組成物

Country Status (6)

Country Link
US (2) US8865188B2 (enExample)
EP (1) EP2747774A4 (enExample)
JP (1) JP2014527072A (enExample)
AU (1) AU2012305714A1 (enExample)
CA (1) CA2847888A1 (enExample)
WO (1) WO2013036973A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519992A (ja) * 2018-12-28 2022-03-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US8865188B2 (en) 2011-09-09 2014-10-21 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
WO2014116730A2 (en) * 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN106279379B (zh) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 一种免疫原HM4-M2e及其制备方法与应用
TWI634899B (zh) * 2016-11-22 2018-09-11 國立臺灣大學 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物
CN107488217A (zh) * 2017-09-13 2017-12-19 华兰生物疫苗有限公司 一种多肽、免疫原性偶联物和流感疫苗
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
JP7417274B2 (ja) * 2018-10-12 2024-01-18 国立研究開発法人理化学研究所 Ｂ型肝炎ウイルス複製阻害剤及びそれを含むｂ型肝炎治療用医薬組成物
CN110125434B (zh) * 2019-05-14 2022-07-29 东南大学 一种光热金纳米材料的制备方法
WO2021163538A1 (en) * 2020-02-13 2021-08-19 The Trustees Of Indiana University Hepadnavirus capsid protein heterodimers and virus-like particles
GB202210507D0 (en) * 2022-07-18 2022-08-31 Univ Dundee Virus-like particles, heterodimeric capsid proteins and methods of production thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124165A2 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2010042743A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric multiplexes, compositions, and methods for using same

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
NZ228948A (en) 1988-05-13 1991-06-25 Phillips Petroleum Co Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
CA2089497A1 (en) 1990-08-15 1992-02-16 Lendon Payne Self-assembling replication defective hybrid virus particles
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
CA2190121A1 (en) 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
EP0762870B1 (en) 1994-05-31 2002-09-11 INEX Pharmaceutical Corp. Virosome-mediated intracellular delivery of therapeutic agents
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP4051416B2 (ja) 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
EA199800475A1 (ru) 1995-11-28 1998-12-24 Дженвек, Инк. Векторы и способы для переноса генов в клетки
US6284494B1 (en) 1995-12-12 2001-09-04 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes
WO1997037680A1 (en) 1996-04-05 1997-10-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
WO1998011916A1 (en) 1996-09-18 1998-03-26 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof
AU738585B2 (en) 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
US6180389B1 (en) 1997-01-03 2001-01-30 The Research And Development Institute, Inc. Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
CA2318981A1 (en) 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles
CZ302092B6 (cs) 1998-02-12 2010-10-06 Immune Complex, Corporation Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek
US6573009B1 (en) 1998-08-05 2003-06-03 Sony Corporation Electrolyte containing a crosslinked compound having ether linkages and a high-molecular compound
WO2000009158A1 (en) 1998-08-12 2000-02-24 University Of Virginia Patent Foundation Assay for assembly of herpes simplex virus capsid
EP1845163A3 (en) 1998-11-05 2007-10-31 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP2351768B1 (en) 1998-12-04 2014-06-18 Biogen Idec MA Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
DE60034947T2 (de) 1999-06-30 2008-01-24 Evotec Ag Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
US20020064520A1 (en) 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
GB9930533D0 (en) 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
EP1301199B1 (en) 2000-07-19 2017-07-12 The Regents of The University of California Methods for therapy of neurodegenerative disease of the brain
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
WO2002044204A2 (en) 2000-12-01 2002-06-06 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Cell-free assembly of lentiviral capsids
DK1407044T4 (en) 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
DE60037263T2 (de) 2000-12-29 2008-10-09 Evotec Ag Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US20050089526A1 (en) 2001-09-06 2005-04-28 Moore John P. Human immunodeficiency virus envelope clycoprotein mutants and uses thereof
US7148343B2 (en) 2001-10-12 2006-12-12 Gentra Systems, Inc. Compositions and methods for using a solid support to purify RNA
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
BR0214350A (pt) 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
JP4810062B2 (ja) 2001-12-17 2011-11-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス（ａａｖ）血清型８の配列
US20040005338A1 (en) 2002-06-20 2004-01-08 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1447079A1 (de) 2003-02-15 2004-08-18 Fraunhofer-Gesellschaft für angewandte Forschung e.V. Vesikel mit chimären Rezeptoren zur Induktion einer gerichteten T-Zellantwort in vivo
WO2004043363A2 (en) 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
JP2004175665A (ja) 2002-11-22 2004-06-24 Japan Science & Technology Agency タンパク質中空ナノ粒子およびそれを用いた薬剤
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
JP2007513261A (ja) 2003-10-15 2007-05-24 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ウイルスファイバー
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20080131928A1 (en) 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
JP2008512484A (ja) 2004-09-09 2008-04-24 ザ ジェネラル ホスピタル コーポレーション 心臓細胞におけるホスファターゼ活性の調節
CN101068567A (zh) 2004-09-17 2007-11-07 科·汉森有限公司 嵌合噬菌体衍生的颗粒，它们的制造方法和用途
CN2763975Y (zh) 2004-12-11 2006-03-08 鸿富锦精密工业（深圳）有限公司 热管式散热装置
WO2006066048A2 (en) 2004-12-17 2006-06-22 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
US20090298955A1 (en) 2005-02-16 2009-12-03 Konica Minolta Holdings, Inc. Altered virus capsid protein and use thereof
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
US20070258889A1 (en) 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US20110104051A1 (en) 2006-03-27 2011-05-05 The Regents Of The University Of California Chemically Modified Viral Capsids as Targeted Delivery Vectors for Diagnostic and Therapeutic Agents
JP2009533350A (ja) * 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
DK2012822T3 (da) 2006-04-28 2010-05-25 Univ Pennsylvania Modificeret adenovirushexonprotein og anvendelser deraf
EP2016174A2 (en) 2006-04-28 2009-01-21 The Trustees of the University of Pennsylvania Modified aav vectors having reduced capsid immunogenicity and use thereof
WO2007136263A1 (en) 2006-05-22 2007-11-29 Nizo Food Research B.V. Protein encapsulated partocles
WO2008021908A2 (en) 2006-08-08 2008-02-21 Board Of Regents Of The University Of Texas Multistage delivery of active agents
WO2008024427A2 (en) 2006-08-23 2008-02-28 Science & Technology Corporation @ Unm A virus-like platform for rapid vaccine discovery
EP2066347A1 (en) 2006-09-28 2009-06-10 Cytos Biotechnology AG Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
WO2008051101A1 (en) 2006-10-25 2008-05-02 Universidade De Coimbra Oral submicron particle delivery system for proteins and process for its production
CA2597878A1 (en) * 2007-09-13 2009-03-13 Ankegens Laboratories Capsid protein and use therefore
WO2010042749A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042751A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US8865188B2 (en) 2011-09-09 2014-10-21 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124165A2 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2010042743A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric multiplexes, compositions, and methods for using same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519992A (ja) * 2018-12-28 2022-03-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド
JP7491932B2 (ja) 2018-12-28 2024-05-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド

Also Published As

Publication number Publication date
EP2747774A2 (en) 2014-07-02
WO2013036973A3 (en) 2013-07-11
US20130156818A1 (en) 2013-06-20
US20150252081A1 (en) 2015-09-10
CA2847888A1 (en) 2013-03-14
WO2013036973A2 (en) 2013-03-14
AU2012305714A1 (en) 2014-03-27
EP2747774A4 (en) 2015-02-11
US8865188B2 (en) 2014-10-21

Similar Documents

Publication Publication Date Title
US8865188B2 (en) Methods and compositions for controlling assembly of viral proteins
JP5902679B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
JP2022101618A (ja) 条件的活性型ポリペプチド
US20110293725A1 (en) Chimeric therapeutics, compositions, and methods for using same
US9017695B2 (en) Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en) Chimeric therapeutics, compositions, and methods for using same
CN113121704B (zh) 基于纳米颗粒的冠状病毒疫苗
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
US7078485B2 (en) N-terminal modified recombinant human endostatin and its production
CN105985447B (zh) 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
EP4477665A1 (en) Stefin a protein variants specifically binding to cd40l, and uses thereof
WO2021083077A1 (zh) 半衰期延长的药物及其文库、以及制备方法和应用
WO2015016608A1 (ko) 항체 및 핵산 결합 펩타이드를 포함하는 핵산 전달용 조성물
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
CN118530961A (zh) 一种用于pe3毒素重构的蛋白组合及其在制备肝癌治疗药物中的应用
WO2025101976A1 (en) Chimeric yeast extracellular vesicles for the enhanced delivery of therapeutic molecules to cells
WO2024066616A1 (zh) 一种高亲和力pd1蛋白偶联物及其应用
CN117327191A (zh) 靶向cd20的笼状蛋白及其应用
WO2022179536A1 (zh) 铁蛋白重链亚基突变体及其应用
CN117916252A (zh) 重组聚糖结合蛋白质及其应用
HK40065797A (zh) 1价ccap生成物的制造方法
JPWO2021083077A5 (enExample)
WO2016138610A1 (zh) 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
HK1232549B (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
HK1232549A1 (en) Tear lipocalin muteins binding il-4 r alpha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170223